Suggested remit: To appraise the clinical and cost effectiveness of dostarlimab with carboplatin and paclitaxel within its marketing authorisation for treating recurrent or advanced endometrial cancer.
Status
|
In progress
|
Technology type
|
Medicine
|
Decision
|
Selected
|
Process |
STA Standard
|
ID number |
3968
|
Provisional Schedule
Final draft guidance |
05 March 2024 - 19 March 2024 |
Expected publication |
03 April 2024 |
Project Team
Project lead |
Thomas Feist |
Email enquiries
External Assessment Group |
Warwick Evidence, Warwick Medical School, University of Warwick |
Stakeholders
Companies sponsors |
GlaxoSmithKline |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
Peaches Womb Cancer Trust |
Professional groups |
Association of Cancer Physicians |
|
Cancer Research UK |
|
Royal College of Physicians |
|
Royal College of Radiologists |
Comparator companies |
MSD |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Care Quality Commission |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |
Date
|
Update
|
05 December 2023
|
Committee meeting: 1 |
16 May 2023
|
Invitation to participate |
27 March 2023
|
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Dostarlimab with carboplatin and paclitaxel for treating recurrent or advanced endometrial cancer have been revised. It is anticipated that the appraisal will begin in mid-May 2023 when we will write to you about how you can get involved. |
30 January 2023 - 20 February 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3968 |
27 October 2022
|
As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Dostarlimab with carboplatin and paclitaxel for treating recurrent or advanced endometrial cancer.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during mid-April 2023 |
24 November 2021
|
In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual